Kronos Bio plans another round of restructuring

8 March 2024
kronosbio-large

US clinical stage biotech Kronos Bio (Nasdaq: KRON) saw its shares edge up 2.3% to $1.32 this morning, on news of further restructuring.

The company announced a plan to optimize its resource allocation, restructure, and extend runway to focus resources on key programs in the Kronos pipeline, including the ongoing Phase I/II study of KB-0742 following the review of additional positive preliminary safety and efficacy data.

Just last November, Kronos announced plans to reduce its workforce by 19% in a bid to allow more resources to be allocated to its drugs KB-0742 and lanraplenib, as well as extend its cash flow until 2026.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology